Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs鈥攁nd how much it sets aside for opioid litigation鈥攎eans combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You鈥檒l also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- AG真人官方-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you鈥檙e waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Q3 FY25 results: Revenue rose 8.7 % YoY to $80.7 B; gross profit +20 % to $2.9 B; operating income +29 % to $867.7 M; diluted EPS climbed 45 % to $3.52. For the nine-month period, sales reached $237.6 B (+10.6 %) and net income was $1.89 B (+25.8 %).
Cash & liquidity: Operating cash flow dropped to $0.74 B (vs $2.48 B last year) as working-capital swings outweighed earnings growth. Cash & equivalents fell to $2.23 B.
Major transaction: Closed the $5.7 B acquisition of 85 % of Retina Consultants of America, adding $1.4 B revenue and $4.8 B goodwill. Financing included $4.5 B USD notes, 鈧�1.0 B notes and a $1.5 B term loan, lifting long-term debt to $8.0 B (from $3.8 B).
Balance sheet: Total assets $74.0 B; goodwill $14.3 B. Accrued opioid-related litigation liability steady at $4.28 B. Share buy-backs of $435 M reduced outstanding shares to 193.9 M.
Segments: U.S. Healthcare Solutions delivered $72.9 B revenue (+8.5 %); International $7.79 B (+10.5 %). FX gains drove $367 M other comprehensive income.
Key watch-points: leverage expansion, potential PharmaLex goodwill impairment ($724 M), rising interest expense and continuing opioid/DEA litigation.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
